Sun Pharma, one of India’s leading pharmaceutical company, plans to expand its specialty business through a combination of licensing and acquisitions.
The company is focusing on developing an internal product pipeline. Moving forward, it will leverage both mergers and acquisitions and in-house development.
As reported by M&A Critique, the upcoming delisting and merger of Taro with Sun Pharma will help the Mumbai-based firm’s growth initiatives. Sun Pharma has grown its specialty business through a series of strategic licensing agreements and acquisitions.
